ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-Claudin 18.2 Antibody-drug Conjugate BL-M05D1

In Sichuan Biokin Pharmaceutical’s pipeline, Claudin18.2 ADC. Its studies are mostly in Stomach Neoplasms · Adenocarcinoma Of Esophagus, led by 2 companies.

Drug pageAnti-Claudin 18.2 Antibody-drug Conjugate BL-M05D1: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Apr 2, 20263 company-led studies, 3 open or runningNext primary completion: Feb 28, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biokin (Shanghai) Biopharmaceuticalits history only22 open or runningphase 3since Apr 2, 2026Apr 1, 2024Jun 2027phase 1 · NCT06349811
Sichuan Biokin Pharmaceuticalits history only11 open or runningphase 1since May 23, 2025May 23, 2025Feb 28, 2027phase 1 · NCT07021066
  • Named in Sichuan Biokin Pharmaceutical’s own pipeline as BL-M05D1 (Claudin18.2 ADC), phase 1, as of Nov 16, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 1, 2024First study: phase 1 study in Locally Advanced or Metastatic Solid TumorsNew to Biokin (Shanghai) BiopharmaceuticalBiokin (Shanghai) Biopharmaceutical · NCT06349811 · 30 planned · China
  2. May 23, 2025Sichuan Biokin Pharmaceutical’s first study: phase 1 study in Adenocarcinoma Of EsophagusNew to Sichuan Biokin PharmaceuticalSichuan Biokin Pharmaceutical · NCT07021066 · 160 enrolled · United States
  3. Apr 2, 2026Phase 3 study in Stomach NeoplasmsPhase 3 reachedBiokin (Shanghai) Biopharmaceutical · NCT07518147 · 438 planned · China

Ahead

  1. Feb 28, 2027Primary completion: phase 1 study in Adenocarcinoma Of EsophagusSichuan Biokin Pharmaceutical · NCT07021066
  2. Jun 2027Primary completion: phase 1 study in Locally Advanced or Metastatic Solid TumorsBiokin (Shanghai) Biopharmaceutical · NCT06349811
  3. Dec 2029Primary completion: phase 3 study in Stomach NeoplasmsBiokin (Shanghai) Biopharmaceutical · NCT07518147

TargetBeta

“Claudin18.2 ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a wild-type Fc-containing immunoglobulin (IgG) monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin 18.2 (CLDN18.2; A2 isoform of claudin-18) (5103F3) ”NCIt, by rule

Other programs on CLDN18

ProgramCompanyFurthest phaseStudies
zolbetuximabruleAstellas Pharmaphase 412
sonesitatug vedotinAstraZenecaphase 37
garetatug rezetecanJiangsu HengRui Medicinephase 37
Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905ruleQilu Pharmaceuticalphase 36
tecotabart vedotinSino Biopharmaceuticalphase 36
arcotatug tavatecanruleInnovent Biologicsphase 35
terallethrinruleFutureGen Biopharmaceutical (Beijing)phase 33
emaretamigruleAstellas Pharmaphase 33
Anti-Claudin 18.2 Antibody-drug Conjugate MK-1200ruleSichuan Kelun Pharmaceuticalphase 23
Anti-Claudin 18.2 Antibody-drug Conjugate ASP546CruleAstellas Pharmaphase 22
givastomigrulei-mab-biopharma-us-limitedphase 22
Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863AstraZenecaphase 21

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07518147Stomach Neoplasms · China3RecruitingBiokin (Shanghai) BiopharmaceuticalDec 2029438
NCT07021066Adenocarcinoma Of Esophagus · United States1Active, not recruitingSichuan Biokin PharmaceuticalFeb 28, 2027160
NCT06349811Locally Advanced or Metastatic Solid Tumors · China1RecruitingBiokin (Shanghai) BiopharmaceuticalJun 202730

How it is read

Names in the registry

  • “BL-M05D1”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.